Skip to main content

Table 1 Specific heart failure patient subgroups representing a challenge for the implementation of LCZ696 in clinical practice

From: Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice

Clinical characteristics Marginally low blood pressure
Hospitalization for AHF
NYHA IV class
Advanced heart failure
Drug therapy-related characteristics ACEi-naïve patients
Intolerance to ACEi or ARB
Low ACEi dose
High ACEi dose
Patients on ARBs therapy
  1. ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; NYHA, New York Heart Association.